The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] Treatment with trifluridine-tipiracil, in combination with bevacizumab, should not be reimbursed in patients with either of the following: 3.1. [...] In 2018, CADTH issued the following reimbursement recommendation for panitumumab (Vectibix) for treatment of patients with wild- type RAS mCRC: • pERC does not recommend the reimbursement of panitumumab in combination with chemotherapy for the first-line treatment of mCRC patients with left-sided primary tumours that express wild-type RAS and who would otherwise be candidates to receive bevacizuma. [...] December 3, 2015 In 2015, CADTH issued the following reimbursement recommendation for panitumumab (Vectibix) for treatment of patients with wild-type RAS mCRC: • The pCODR Expert Review Committee (pERC) recommends funding panitumumab in addition to combination chemotherapy conditional on cost- effectiveness being improved to an acceptable level, for the treatment of patients with WT RAS mCRC in th.
- Pages
- 10
- Published in
- Canada
